keyword
MENU ▼
Read by QxMD icon Read
search

Biomarkers CKD

keyword
https://www.readbyqxmd.com/read/29791896/deterioration-of-cortical-bone-microarchitecture-critical-component-of-renal-osteodystrophy-evaluation
#1
Ashish K Sharma, Nigel D Toussaint, Rosemary Masterson, Stephen G Holt, Chamith S Rajapakse, Peter R Ebeling, Sindhu T Mohanty, Paul Baldock, Grahame J Elder
BACKGROUND: Cortical bone is a significant determinant of bone strength and its deterioration contributes to bone fragility. Thin cortices and increased cortical porosity have been noted in patients with chronic kidney disease (CKD), but the "Turnover Mineralization Volume" classification of renal osteodystrophy does not emphasize cortical bone as a key parameter. We aimed to assess trabecular and cortical bone microarchitecture by histomorphometry and micro-CT in patients with CKD G5 and 5D (dialysis)...
May 23, 2018: American Journal of Nephrology
https://www.readbyqxmd.com/read/29777021/serum-6-bromotryptophan-levels-identified-as-a-risk-factor-for-ckd-progression
#2
Adrienne Tin, Girish Nadkarni, Anne M Evans, Cheryl A Winkler, Erwin Bottinger, Casey M Rebholz, Mark J Sarnak, Lesley A Inker, Andrew S Levey, Michael S Lipkowitz, Lawrence J Appel, Dan E Arking, Josef Coresh, Morgan E Grams
Background Metabolite levels reflect physiologic homeostasis and may serve as biomarkers of disease progression. Identifying metabolites associated with APOL1 risk alleles-genetic variants associated with CKD risk commonly present in persons of African descent-may reveal novel markers of CKD progression relevant to other populations. Methods We evaluated associations between the number of APOL1 risk alleles and 760 serum metabolites identified via untargeted profiling in participants of the African American Study of Kidney Disease and Hypertension (AASK) ( n =588; Bonferroni significance threshold P <6...
May 18, 2018: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/29775888/therapeutic-impact-of-rhuepo-on-abnormal-platelet-app-bace-1-presenilin-1-adam-10-and-a%C3%AE-expressions-in-chronic-kidney-disease-patients-with-cognitive-dysfunction-like-alzheimer-s-disease-a-pilot-study
#3
Vinothkumar G, Krishnakumar S, Sureshkumar, Shivashekar G, Sreedhar S, Preethikrishnan, Dinesh S, Sundaram A, Balakrishnan D, Riya, Venkataraman P
BACKGROUND: Cognitive dysfunction is reported to be a major cause of morbidity in chronic kidney disease (CKD). The senile plaques (SPs) in the brain are one of the most pathophysiological characteristics of cognitive dysfunction and its major constituent amyloid β (Aβ) released from amyloid precursor protein (APP) by β (BACE1) and γ (presenilin 1) secretases . Platelets contain more than 95% of the circulating APP and implicate as a candidate biomarker for cognitive decline. Recombinant human erythropoietin (rHuEPO) is a standard therapy for anemia in CKD and also acts as a neuroprotective agent...
May 14, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29771383/relationship-of-fibroblast-growth-factor-21-with-kidney-function-and-albuminuria-multi-ethnic-study-of-atherosclerosis
#4
Sahapab Anuwatmatee, Matthew A Allison, Michael G Shlipak, Robyn L McClelland, Holly Kramer, Shudi Tang, Liming Hou, Kerry-Anne Rye, Kwok Leung Ong
Background: Fibroblast growth factor 21 (FGF21) may play a role in the development of chronic kidney disease (CKD). We therefore investigated the relationship of plasma FGF21 levels with kidney function and albuminuria in the Multi-Ethnic Study of Atherosclerosis (MESA). Methods: The analysis included 5724 MESA participants ages 45-84 years between 2000 and 2002, free of clinically apparent cardiovascular disease (CVD). Participants were followed up in person at four additional clinic visits over 10 years...
May 15, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29764395/longitudinal-changes-in-bone-and-mineral-metabolism-after-cessation-of-cinacalcet-in-dialysis-patients-with-secondary-hyperparathyroidism
#5
Irene Ruderman, Edward R Smith, Nigel D Toussaint, Tim D Hewitson, Stephen G Holt
BACKGROUND: The calcimimetic agent cinacalcet is effective for the management of secondary hyperparathyroidism (SHPT) in dialysis patients. Changes to reimbursement of cinacalcet in Australia provided an opportunity to assess effects of medication cessation on biochemical and clinical outcomes in dialysis patients, including changes to novel biomarkers such as calciprotein particles (CPP). CPP are nanoparticles of mineral and protein in the circulation associated with increased vascular calcification in patients with chronic kidney disease...
May 15, 2018: BMC Nephrology
https://www.readbyqxmd.com/read/29748326/a-novel-method-for-rapid-bedside-measurement-of-gfr
#6
Dana V Rizk, Daniel Meier, Ruben M Sandoval, Teresa Chacana, Erinn S Reilly, Jesse C Seegmiller, Emmanuel DeNoia, James S Strickland, Joseph Muldoon, Bruce A Molitoris
Background Direct quantitative measurement of GFR (mGFR) remains a specialized task primarily performed in research settings. Multiple formulas for estimating GFR have been developed that use the readily available endogenous biomarkers creatinine and/or cystatin C. However, eGFR formulas have limitations, and an accurate mGFR is necessary in some clinical situations and for certain patient populations. We conducted a prospective, open-label study to evaluate a novel rapid technique for determining plasma volume and mGFR...
May 10, 2018: Journal of the American Society of Nephrology: JASN
https://www.readbyqxmd.com/read/29741651/serum-phosphate-optimal-timing-and-range-associated-with-patients-survival-in-haemodialysis-the-cosmos-study
#7
José L Fernández-Martín, Adriana Dusso, Pablo Martínez-Camblor, Maria P Dionisi, Jürgen Floege, Markus Ketteler, Gérard London, Francesco Locatelli, José L Górriz, Boleslaw Rutkowski, Willem-Jan Bos, Christian Tielemans, Pierre-Yves Martin, Rudolf P Wüthrich, Drasko Pavlovic, Miha Benedik, Diego Rodríguez-Puyol, Juan J Carrero, Carmine Zoccali, Jorge B Cannata-Andía
Background: Serum phosphate is a key parameter in the management of chronic kidney disease-mineral and bone disorder (CKD-MBD). The timing of phosphate measurement is not standardized in the current guidelines. Since the optimal range of these biomarkers may vary depending on the duration of the interdialytic interval, in this analysis of the Current management of secondary hyperparathyroidism: a multicentre observational study (COSMOS), we assessed the influence of a 2- (midweek) or 3-day (post-weekend) dialysis interval for blood withdrawal on serum levels of CKD-MBD biomarkers and their association with mortality risk...
May 7, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29740119/circulating-fibroblast-growth-factor-23-levels-are-associated-with-an-increased-risk-of-anemia-development-in-patients-with-nondialysis-chronic-kidney-disease
#8
Ki Heon Nam, Hyoungnae Kim, Seong Yeong An, Misol Lee, Min-Uk Cha, Jung Tak Park, Tae-Hyun Yoo, Kyu-Beck Lee, Yeong-Hoon Kim, Su-Ah Sung, Joongyub Lee, Shin-Wook Kang, Kyu Hun Choi, Curie Ahn, Seung Hyeok Han
Fibroblast growth factor-23 (FGF23) is an established biomarker of adverse outcomes in patients with chronic kidney disease (CKD). Several cross-sectional studies have suggested a possible association between FGF23 and anemia in these patients. In this large-scale prospective cohort study, we investigated this relationship and examined whether high FGF23 levels increase the risk of incident anemia. This prospective longitudinal study included 2,089 patients from the KoreaN cohort study for Outcome in patients With CKD...
May 8, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29738042/biomarkers-of-cardio-renal-syndrome-in-uremic-myocardiopathy-animal-model
#9
Laura Mattana Dionísio, Mateus Justi Luvizoto, Caroline Gribner, Danielle Carneiro, Viviane Carvalho, Franciele Robes, Marcos Sheidemantel, Fabiane Rego, Lúcia de Noronha, Roberto Pecoits-Filho, Aline Borsato Hauser
INTRODUCTION: Cardio-renal syndrome subtype 4 (CRS4) is a condition of primary chronic kidney disease that leads to reduction of cardiac function, ventricular hypertrophy, and risk of cardiovascular events. OBJECTIVE: Our aim was to understand the mechanisms involved on the onset of CRS4. METHODS: We used the nephrectomy 5/6 (CKD) animal model and compared to control (SHAM). Serum biomarkers were analyzed at baseline, 4, and 8 weeks. After euthanasia, histology and immunohistochemistry were performed in the myocardium...
May 7, 2018: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
https://www.readbyqxmd.com/read/29737025/renal-safety-after-one-year-of-sofosbuvir-based-therapy-for-chronic-hepatitis-c-a-brazilian-real-life-study
#10
T Medeiros, N F Rosário, G N Saraiva, T G Andrade, A A Silva, J R Almeida
WHAT IS KNOWN AND OBJECTIVE: Sofosbuvir(SOF)-based regimens have been administrated with excellent efficacy in chronic hepatitis C. Few uncontrolled ("real-life") studies consider the assessment of renal function when evaluating their post-treatment outcomes. This study aims to evaluate renal biomarkers in a "real-life" experience with chronic hepatitis C patients treated with SOF therapy in a long-term follow-up. METHODS: Serum and urinary biomarkers were analysed before, at the end of therapy (EoT), after 12 weeks (sustained virological response-SVR) and one year (1y) post-treatment...
May 7, 2018: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/29698460/growth-differentiation-factor-15-and-fibroblast-growth-factor-23-are-associated-with-mortality-in-type-2-diabetes-an-observational-follow-up-study
#11
Marie Frimodt-Møller, Bernt Johan von Scholten, Henrik Reinhard, Peter Karl Jacobsen, Tine Willum Hansen, Frederik Ivar Persson, Hans-Henrik Parving, Peter Rossing
OBJECTIVES: Two biomarkers, growth differentiation factor 15 (GDF-15) and fibroblast growth factor 23 (FGF-23)), reflecting different aspects of renal pathophysiology, were evaluated as determinants of decline in estimated glomerular filtration rate (eGFR), incident cardiovascular disease (CVD) and all-cause mortality in patients with type 2 diabetes (T2D) and microalbuminuria, but without clinical cardiac disease. MATERIALS AND METHODS: Prospective study including 200 T2D patients...
2018: PloS One
https://www.readbyqxmd.com/read/29697035/serum-n-terminal-pro-brain-natriuretic-peptide-level-is-associated-with-the-development-of-chronic-kidney-diseases-in-patients-with-type-2-diabetes
#12
Ryo Sawada, Yoshitaka Hashimoto, Takafumi Senmaru, Muhei Tanaka, Emi Ushigome, Masahiro Yamazaki, Michiaki Fukui
BACKGROUND AND OBJECTIVE: Previous studies revealed the association between serum N-terminal pro-brain natriuretic peptide (NT-proBNP) level and chronic kidney diseases (CKD) in general population. However, little is known about the association between serum NT-proBNP level and incident CKD in patients with type 2 diabetes. Thus, we investigated the impact of serum NT-proBNP level on incident CKD in patients with type 2 diabetes. METHOD: We enrolled 211 type 2 diabetic patients without CKD in this cohort study...
April 25, 2018: Endocrine, Metabolic & Immune Disorders Drug Targets
https://www.readbyqxmd.com/read/29694626/association-of-different-biomarkers-of-renal-function-with-d-dimer-levels-in-patients-with-type-1-diabetes-mellitus-renal-biomarkers-and-d-dimer-in-diabetes
#13
Caroline Pereira Domingueti, Rodrigo Bastos Fóscolo, Luci Maria S Dusse, Janice Sepúlveda Reis, Maria das Graças Carvalho, Karina Braga Gomes, Ana Paula Fernandes
Objective This study aimed to evaluate the association between different renal biomarkers with D-Dimer levels in diabetes mellitus (DM1) patients group classified as: low D-Dimer levels (< 318 ng/mL), which included first and second D-Dimer tertiles, and high D-Dimer levels (≥ 318 ng/mL), which included third D-Dimer tertile. Materials and methods D-Dimer and cystatin C were measured by ELISA. Creatinine and urea were determined by enzymatic method. Estimated glomerular filtration rate (eGFR) was calculated using CKD-EPI equation...
February 2018: Archives of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29691773/etelcalcetide-for-treating-secondary-hyperparathyroidism-an-evidence-review-group-evaluation-of-a-nice-single-technology-appraisal
#14
Micah Rose, Jonathan Shepherd, Petra Harris, Karen Pickett, Joanne Lord
The manufacturer of the calcimimetic drug etelcalcetide was invited to make an evidence submission as part of the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA) programme. Within this submission, they reported evidence on the clinical and cost effectiveness of etelcalcetide for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on haemodialysis. The Southampton Health Technology Assessments Centre (SHTAC), part of the Wessex Institute at the University of Southampton, was the independent Evidence Review Group (ERG) commissioned to appraise the company's submission...
April 25, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29684593/renal-function-n-terminal-pro-b-type-natriuretic-peptide-propeptide-big-endothelin-and-patients-with-heart-failure-and-preserved-ejection-fraction
#15
Ingrid Gergei, Bernhard K Krämer, Hubert Scharnagl, Tatjana Stojakovic, Winfried März
Renal dysfunction may limit the clinical application of NT-proBNP in the diagnosis of heart failure. In general practice, where echocardiography is not readily available, a biomarker for the diagnosis of a heart failure with preserved ejection fraction (HFpEF) would be useful. Since cardiac diseases frequently coincide with renal disease, there is a high need of valid risk stratification methods in patients affected with both. We therefore examined NT-proBNP and another biomarker, Big-Endothelin-1, as a marker of HFpEF in patients with CKD...
April 20, 2018: Peptides
https://www.readbyqxmd.com/read/29682152/thrombomodulin-as-a-new-marker-of-endothelial-dysfunction-in-chronic-kidney-disease-in-children
#16
Dorota Drożdż, Monika Łątka, Tomasz Drożdż, Krystyna Sztefko, Przemko Kwinta
Endothelial dysfunction (ED) and oxidative stress are potential new pathomechanisms of cardiovascular diseases in patients with chronic kidney disease (CKD). The aim of the study was to assess the association between endothelial dysfunction, oxidative stress biomarkers, and cardiovascular risk factors in children with CKD. Serum oxidized LDL (oxLDL), protein carbonyl group, urea, creatinine, cystatin C, thrombomodulin, asymmetric dimethylarginine (ADMA), von Willebrand factor, brain natriuretic peptide (BNP), lipids, high sensitivity C-reactive protein, intercellular adhesion molecule-1 levels, and albuminuria were measured...
2018: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/29668990/vitamin-d-receptor-activation-raises-soluble-thrombomodulin-levels-in-chronic-kidney-disease-patients-a-double-blind-randomized-trial
#17
Graziella D'arrigo, Patrizia Pizzini, Sebastiano Cutrupi, Rocco Tripepi, Giovanni Tripepi, Francesca Mallamaci, Carmine Zoccali
Background: Thrombomodulin (TM) is a proteoglycan highly represented in the endothelial glycocalix that regulates the haemostasis and the endothelial response to inflammation. High soluble TM levels underlie a lower risk for coronary heart disease in population studies. Activation of vitamin D receptor (VDR) upregulates TM, but the effect of this intervention on soluble TM has never been tested in chronic kidney disease (CKD) patients. Methods: We performed a post hoc analysis of a 12 weeks double blind, randomized, placebo-controlled trial testing the effect of VDR activation by paricalcitol (PCT) on endothelium-dependent flow-mediated vasodilatation (FMD) in the forearm (ClinicalTrials...
April 13, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29668468/clinical-proteomics-in-kidney-disease-from-discovery-to-clinical-application
#18
Martin Pejchinovski, Harald Mischak
Proteome analysis has been applied in multiple studies in the context of chronic kidney disease, aiming at improving our knowledge on the molecular pathophysiology of the disease. The approach is generally based on the hypothesis that proteins are key in maintaining kidney function, and disease is a clinical consequence of a significant change of the protein level. Knowledge on critical proteins and their alteration in disease should in turn enable identification of ideal biomarkers that could guide patient management...
December 1, 2017: Prilozi (Makedonska Akademija Na Naukite i Umetnostite. Oddelenie za Medicinski Nauki)
https://www.readbyqxmd.com/read/29665969/copeptin-plasma-levels-are-associated-with-decline-of-renal-function-in-patients-with-type-2-diabetes-mellitus
#19
Maria De La Luz Villela-Torres, Ana Edith Higareda-Mendoza, Anel Gómez-García, Alfonso Rafael Alvarez-Paredes, Elvia García-López, Peter Stenvikel, Harvest F Gu, Abbul Rashid-Qureshi, Bengt Lindholm, Cleto Alvarez-Aguilar
BACKGROUND: Chronic kidney disease (CKD) is a leading complication of type 2 diabetes mellitus (T2DM) and is considered as a public health problem. Copeptin is a surrogate marker of arginine vasopressin (AVP) system and is proposed as a biomarker of decline renal function. OBJECTIVE: Evaluate whether plasma copeptin levels may be used as a biomarker of decline renal function in patients with T2DM. RESEARCH DESIGN AND METHODS: A total of 480 patients with T2DM and different stages of CKD were included...
April 14, 2018: Archives of Medical Research
https://www.readbyqxmd.com/read/29661746/effects-of-oral-vitamin-d-3-supplementation-in-stage-3-chronic-kidney-disease-subjects-insulin-resistance-syndrome-and-hormonal-disturb-interactions
#20
Amina Tahar, Faiza Zerdoumi, Messaoud Saidani, Lakhdar Griene, Elhadj-Ahmed Koceir
The 1-25-hydroxyvitamine D (1-25OHD) or calcitriol deficiency in chronic kidney disease (CKD) patients was associated with increases vascular calcification risk, nephrons reduction, bone deficit and cardiovascular mortality by atherosclerosis. The objective of this study was to investigate the pleiotropic effects of 200.000 IU (D200 group) every 3 months versus 30.000 IU (D30 group) every month dose vitamin D supplementation in stage 3 CKD patients. A cohort of 132 adult subjects was randomized into 2 groups according to dose vitamin D supplementation in deficient subjects (25OHD <50 nmol/L or <20 ng/mL)...
April 16, 2018: Annales de Biologie Clinique
keyword
keyword
24252
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"